FGF21 and metabolic dysfunction-associated steatohepatitis: In addition, a clinical trial evaluating the safety and efficacy of efruxifermin, a long-acting Fc-FGF21 fusion protein, in nonalcoholic steatohepatitis showed that efruxifermin intervention significantly reduced the hepatic fat fraction in patients with stage F1-F3 nonalcoholic steatohepatitis with an acceptable safety profile (121).